The Patent and Trademark Office’s pilot program to expedite patent applications for cancer immunotherapy treatments is moving fast.
Review time for the applications is averaging a little more than four months, Gary Nickol, supervisory patent examiner at the U.S. Patent and Trademark Office, said Aug. 2.
The fast-track program, also known as Patents 4 Patients, was part of the Obama administration’s National Cancer Moonshot initiative to accelerate the fight against cancer. It had been scheduled to end in June but was extended until Dec. 31, 2018, due to continued interest.
So far, more than 111 petitions requesting participation in the pilot program have been filed since the PTO launched the program June 29, 2016, Nickol said. He spoke at the Biotechnology/Chemical/Pharmaceutical Customer Partnership webinar.
Patent applications featuring any method of treating or preventing a malignancy by boosting the immune system are eligible to participate. An applicant will get an answer on patentability within 12 months of its petition for accelerated processing being accepted.
“We are really trying to work to get them out,” Nickol said.
Program applicants include independent inventors, universities, research institutions, hospitals, medical centers, government agencies, and large and small companies, the PTO said.
“As long as you have one claim related to immunotherapy, we’ll take a look at the petition,” Nickol said.
Immunotherapy is a type of cancer treatment designed to boost the body’s natural defenses by using substances either made by the body or in a laboratory to improve or restore immune system function.
AstraZeneca Plc, Bristol-Myers Squibb Co., Merck & Co., and Roche Holding AG are among companies in the race to develop immunotherapies for cancer patients.
Stay on top of new developments in health law and regulation with a free trial to the Health Law Resource Center.
Learn more about Bloomberg Law and sign up for a free trial.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to firstname.lastname@example.org.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to email@example.com.
Put me on standing order
Notify me when new releases are available (no standing order will be created)